Experimental DNA vaccine aims to train immune system against prostate cancer
NCT ID NCT07090148
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This early-phase trial tests whether an experimental DNA vaccine (pTVG-HP) combined with the immunotherapy drug nivolumab and targeted radiation can help the immune system attack prostate cancer that has returned in a few spots. The study involves 14 men whose cancer has come back after prostate removal but who still have normal testosterone levels. The main goals are to see if the treatment can lower PSA levels and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin - Madison
RECRUITINGMadison, Wisconsin, 53705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.